Announcement on Convening the 2025 Semi-annual Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
View Attachment
Announcement on Convening the 2025 Semi-annual Performance Briefing
Filed with SSE ·
6ix hasn’t read this filing yet.
Aurisco Pharmaceutical Co. Ltd. on 6ix
Earlier from Aurisco Pharmaceutical
- Announcement on Shareholding Reduction Plan for Partial Senior Executives
- Announcement on Redemption upon Maturity of Partial Idle Raised Funds Used for Cash Management
- Announcement on Interest Payment for "Aurisco Convertible Bonds" in 2025
- Announcement on 2025 Tracking Credit Rating Results of "Aurisco Convertible Bonds"
- Announcement on Passing On-site Inspection by FDA
Later from Aurisco Pharmaceutical
- Announcement on Redemption of Partial Idle Raised Funds Used for Cash Management upon Expiration and Continuously Conducting Cash Management
- Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
- Announcement on Change of Sponsor Representative for Continuous Supervision
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Announcement on Achieving Conditions for Lifting Sales Restrictions and Listing of the 3rd Restricted Stock Trading Period under the 2022 Restricted Stock Incentive Plan
Follow Aurisco Pharmaceutical into a list and get an email when it puts out news.
Follow Aurisco Pharmaceutical